SZTZ-Ffm

CAR-T-Cell study in pediatric patients

Pediatric patients with relapsed leukemia can now be enrolled in the CCTL019B2202 study. This multicenter phase II study investigates the efficiency and saftety of CTL019 (CAR-T-Cells) in pediatric patients with refractory or relapsed acute lymphoblastic B-Cell-Leukemia. Children and adolescents at the age of 3-21 years with CD19-positive relapse after allogeneic stem cell transplantation can be enrolled. They should not have received Blinatumomab before.